A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer

被引：0
|
作者：
Vukelja, S.
Rugo, H.
Vogel, C.
Borson, R.
Tan-Chiu, E.
Birkner, M.
Holden, S. N.
Klencke, B.
O'Shaughnessy, J.
Burris, H. A.
机构：
[1] Tyler Canc Ctr, Tyler, TX USA
[2] UCSF Comprehens Canc Ctr, San Francisco, CA USA
[3] Lynn Canc Inst, Boca Raton, FL USA
[4] St Louis Canc & Breast Inst, St Louis, MO USA
[5] Genentech Inc, San Francisco, CA 94080 USA
[6] Baylor Sammons Canc Ctr, Dallas, TX USA
[7] Sarah Cannon Canc, Nashville, TN USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：71S / 71S
页数：1
相关论文
共 50 条
  • [21] A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer
    Hu, Xichun
    Zhang, Jian
    Ji, Dongmei
    Xia, Gang
    Ji, Yanping
    Xiong, Gaozhun
    Liang, Xuejun
    CANCER RESEARCH, 2020, 80 (04)
  • [22] Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer
    Pegram, M.
    Hamilton, E.
    Tan, A. R.
    Storniolo, A. M.
    Elgeioushi, N.
    Marshall, S.
    Abdullah, S.
    Patel, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [23] Trastuzumab-DM1 antibody-drug conjugate is efficacious in lapatinib-resistant breast cancer cells
    Li, Guangmin
    Guo, Jun
    Mohan, Sankar
    Pandita, Ajay
    Liu, Bonnie
    Phillips, Gail Lewis
    CANCER RESEARCH, 2009, 69
  • [24] Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer
    Burris, Howard A., III
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (06) : 807 - 819
  • [25] Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer
    Krop, Ian
    Winer, Eric P.
    CLINICAL CANCER RESEARCH, 2014, 20 (01) : 15 - 20
  • [26] Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer
    Baron, Jessica M.
    Boster, Bonnie L.
    Barnett, Chad M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2015, 21 (02) : 132 - 142
  • [27] Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2
    Abelman, Rachel Occhiogrosso
    Medford, Arielle
    Spring, Laura
    Bardia, Aditya
    CANCER JOURNAL, 2022, 28 (06): : 423 - 428
  • [28] Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
    Lu, Dan
    Girish, Sandhya
    Gao, Yuying
    Wang, Bei
    Yi, Joo-Hee
    Guardino, Ellie
    Samant, Meghna
    Cobleigh, Melody
    Rimawi, Mothaffar
    Conte, Pierfranco
    Jin, Jin Yan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 399 - 410
  • [29] Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer
    Li, Chunze
    Wang, Bei
    Lu, Dan
    Jin, Y.
    Gao, Yuying
    Matsunaga, Kiyoshi
    Igawa, Yuriko
    Nijem, Ihsan
    Lu, Michael
    Strasak, Alexander
    Chernyukhin, Nataliya
    Girish, Sandhya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 547 - 558
  • [30] Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer
    Lambert, John M.
    Chari, Ravi V. J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (16) : 6949 - 6964
12345